Skip to main content
Crescita Therapeutics Inc. logo

Crescita Therapeutics Inc. — Investor Relations & Filings

Ticker · CTX ISIN · CA2258471028 TSX Manufacturing
Open in API
Filings indexed 286 across all filing types
Latest filing 2026-05-21 Remuneration Information
Country CA Canada
Listing TSX CTX

About Crescita Therapeutics Inc.

https://www.crescitatherapeutics.com/

Crescita Therapeutics Inc. is a commercial dermatology company focused on the development, manufacturing, and commercialization of topical therapeutic products. The company leverages in-house research and development (R&D) and manufacturing capabilities to maintain an innovation-driven portfolio. This portfolio encompasses both prescription drug products and non-prescription skincare products (including over-the-counter and in-clinic formulations). Crescita's offerings are primarily utilized for the treatment and care of skin conditions, diseases, and their associated symptoms, with additional development efforts directed toward topical pain management solutions. The company distributes its products across North American and international markets.

Recent filings

Filing Released Lang Actions
Statement of executive compensation (form 51-102F6) - English.pdf
Remuneration Information Classification · 93% confidence The document is a detailed Statement of Executive Compensation for the fiscal year ended December 31, 2025, including a Compensation Discussion and Analysis, descriptions of the Compensation, Corporate Governance and Nominating Committee, and executive pay elements, prepared under Canadian National Instrument Form 51-102F6. This corresponds directly to remuneration disclosures for directors and named executive officers, matching the “Remuneration Information (Code: DEF 14A)” category.
2026-05-21 English
News release - English.pdf
M&A Activity Classification · 85% confidence The document is a press release announcing that Crescita Therapeutics has obtained a final court order approving a Plan of Arrangement for the acquisition of its shares by ClinActiv, describing transaction terms, expected closing and delisting. It is not the full merger proxy or regulatory tender‐offer forms, but clearly falls under merger/takeover announcement activity. Therefore it is classified as M&A Activity (TAR).
2026-05-20 English
Report of voting results.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 93% confidence The document is a report of voting results from a special shareholders meeting held on May 14, 2026, summarizing votes for and against an Arrangement Resolution. This matches the definition for Declaration of Voting Results & Voting Rights Announcements (Code: DVA).
2026-05-14 English
News release - English.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is a press release announcing the special meeting of shareholders and reporting the vote tally on the Arrangement Resolution for the acquisition by ClinActiv Holdings. It provides the number and percentage of votes for and against – a clear declaration of voting results. This fits the definition of “Declaration of Voting Results & Voting Rights Announcements (Code: DVA).”
2026-05-14 English
52-109F2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings
2026-05-11 English
Interim financial statements/report – English.pdf
Regulatory Filings
2026-05-11 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.